Emergent Biosolutions

OverviewSuggest Edit

Emergent Biosolutions is a global specialty biopharmaceutical company offering specialized products that address medical needs and emerging health threats. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Emergent Biosolutions focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats. 

TypePublic
Founded1998
HQGaithersburg, US
Websiteemergentbiosolutions.com
Employee Ratings3

Latest Updates

Employees (est.) (Feb 2019)1,705(+36%)
Job Openings127
Revenue (FY, 2017)$560.9 M(+15%)
Share Price (Oct 2019)$53.8

Key People/Management at Emergent Biosolutions

Fuad El-Hibri

Fuad El-Hibri

Executive Chairman of the Board of Directors
Daniel J. Abdun-Nabi

Daniel J. Abdun-Nabi

CEO
Robert G. Kramer

Robert G. Kramer

President and Chief Operating Officer
Richard S. Lindahl

Richard S. Lindahl

Executive Vice President, Chief Financial Officer and Treasurer
Adam R. Havey

Adam R. Havey

Executive Vice President, Business Operations
Atul Saran

Atul Saran

Executive Vice President, Corporate Development and General Counsel
Show more

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Baltimore, Hattiesburg, Lansing and in 6 other locations
Gaithersburg, US (HQ)
400 Professional Dr #400
Baltimore, US
1111 S Paca St
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Lansing, US
3500 N Martin Luther King Jr Blvd
Seattle, US
2401 4th Ave #1050
Show all (11)

Emergent Biosolutions Financials and Metrics

Emergent Biosolutions Revenue

Emergent Biosolutions's revenue was reported to be $560.87 m in FY, 2017
USD

Net income (Q1, 2019)

(26.0m)

Market capitalization (16-Oct-2019)

2.8b

Closing stock price (16-Oct-2019)

53.8
Emergent Biosolutions's current market capitalization is $2.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

312.7m404.5m522.8m488.8m560.9m

Revenue growth, %

21%0%

Cost of goods sold

62.1m

Gross profit

250.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

89.1m53.9m110.3m138.0m63.6m126.1m164.9m111.0m101.5m142.9m116.9m100.8m149.4m117.8m220.2m173.7m

Cost of goods sold

20.1m

Gross profit

69.0m

Gross profit Margin, %

77%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

179.3m280.5m312.8m271.5m178.3m

Accounts Receivable

60.6m58.8m120.8m138.5m143.7m

Inventories

14.6m65.7m76.9m74.0m142.8m

Current Assets

273.1m432.2m538.6m510.2m485.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

30.3m36.7m62.9m51.8m82.6m

Depreciation and Amortization

19.0m42.6m

Inventories

518.0k4.2m(11.3m)(9.0m)6.1m

Accounts Payable

(551.0k)(9.3m)4.7m(14.8m)16.1m(7.0m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

15.0m(20.2m)(15.2m)6.6m(21.5m)(7.4m)29.5m4.0m(7.0m)14.4m10.5m15.1m48.7m45.2m66.2m

Depreciation and Amortization

13.5m6.8m15.3m24.3m8.5m17.3m25.9m8.8m17.8m28.2m10.2m20.1m29.9m12.4m24.7m37.1m

Inventories

(1.2m)(4.0m)1.2m4.7m(16.5m)(19.0m)(14.4m)(11.3m)(19.7m)(16.2m)3.3m3.5m5.1m(12.4m)3.4m17.1m

Accounts Payable

(1.6m)(10.7m)(10.4m)(11.2m)1.1m2.1m1.9m385.0k11.3m(1.3m)81.0k4.2m3.0m3.6m(4.4m)(5.7m)
Show all financial metrics

Emergent Biosolutions Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Adapt PharmaAugust 29, 2018$735 m
PaxVaxAugust 10, 2018$270 m

Emergent Biosolutions Online and Social Media Presence

Embed Graph

Emergent Biosolutions News and Updates

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Produ…

Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2019, recent business developments, revenue guidance for the fo…

Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued at appr…

Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4.

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

GAITHERSBURG, Md., Sept. 03, 2019 (GLOBE NEWSWIRE) -- In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Prepared…

Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

AV7909 next generation vaccine positioned as primary solution for U.S. government’s anthrax preparedness and response efforts AV7909 next generation vaccine positioned as primary solution for U.S. government’s anthrax preparedness and response efforts
Show more

Emergent Biosolutions Blogs

BIO International 2019 with Sean Kirk

BIO International 2019 with Sean Kirk eric.li September 25, 2019 ​Pharma's Almanac TV published a video interview from BIO International 2019 with Sean Kirk, executive vice president, manufacturing and technical operations, in which he discusses Emergent's cultural foundations based …

Emergent Biosolutions Frequently Asked Questions

  • When was Emergent Biosolutions founded?

    Emergent Biosolutions was founded in 1998.

  • Who are Emergent Biosolutions key executives?

    Emergent Biosolutions's key executives are Fuad El-Hibri, Daniel J. Abdun-Nabi and Robert G. Kramer.

  • How many employees does Emergent Biosolutions have?

    Emergent Biosolutions has 1,705 employees.

  • Who are Emergent Biosolutions competitors?

    Competitors of Emergent Biosolutions include Adverse Health, Tristel and Haemonetics.

  • Where is Emergent Biosolutions headquarters?

    Emergent Biosolutions headquarters is located at 400 Professional Dr #400, Gaithersburg.

  • Where are Emergent Biosolutions offices?

    Emergent Biosolutions has offices in Gaithersburg, Baltimore, Hattiesburg, Lansing and in 6 other locations.

  • How many offices does Emergent Biosolutions have?

    Emergent Biosolutions has 11 offices.